Trials / Withdrawn
WithdrawnNCT00751608
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of APL180 on endothelial function measured by forearm venous occlusion plethysmography in patients with familial hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL180 | |
| DRUG | APL180 | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-09-12
- Last updated
- 2016-09-23
Source: ClinicalTrials.gov record NCT00751608. Inclusion in this directory is not an endorsement.